Mark Preston

Washington, D.C.

Vice President, Political and Special Events Programming and Senior Political Analyst at CNN

CNN VP/Senior Political Analyst Peabody; 4x Emmy winner/8x Emmy nominated; Cronkite A big fan of sports teams from God's Country ... if you have to ask ...

Featured in: Favicon

cnn.com

linkedin.com Favicon

msn.com

cbsnews.com Favicon

nature.com Favicon

telegraph.co.uk Favicon

zdnet.com

flipboard.com Favicon

vanityfair.com Favicon

jamanetwork.com + 86 more

Articles

The facts about our ownership

Oct 31, 2024 | grosvenor.com | Mark Preston

We believe in the moral duty to pay our fair share of tax and abide by the rule of law that determines it We are a privately owned organisation but transparently report on our commercial and public interest activities in a way that is comparable to listed businesses Our commercial business assets are owned by a series of UK resident trusts which pay all applicable taxes including income tax, capital gains tax and inheritance tax We pay inheritance tax through a recurring 6% payment on the...
Taiga Being Sold To European Electric Boat Builder

Oct 11, 2024 | snowgoer.com | John Prusak |Mark Preston |Chris Woldrich |David Schwartz

The Quebec-based company that had plans to bring electric options to the snowmobile, personal watercraft and other powersports markets has a new owner. Taiga Motors announced late on Thursday, October 10, that it is being acquired by a Euro-based electric boat builder. No terms of the deal were disclosed. In July, Taiga filed for the Canadian equivalent of Chapter 11 bankruptcy, which afforded it protection from debtors while restructuring.
Intravesical Gemcitabine-Docetaxel Shows Durable Response in Recurrent High-Risk NMIBC After BCG - Mark Preston

Mar 12, 2024 | urotoday.com | Mark Preston

Read the Full Video TranscriptSam Chang: Hello, my name is Sam Chang. I'm a urologist in Nashville, Tennessee, and I work at Vanderbilt University Medical Center. We're quite fortunate to have Dr. Mark Preston. Mark is actually an associate professor at the Brigham and Women's Dana-Farber conglomeration of institutions associated with Harvard Medical School. He really doesn't need an introduction.
Postradical prostatectomy prostate‐specific antigen outcomes after 6 versus 18 months of perioperative androgen‐deprivation therapy in men with localized, unfavorable intermediate-risk or high‐risk prostate cancer: Results of part 2 of a randomized phase

Jan 2, 2024 | acsjournals.onlinelibrary.wiley.com | Rana R. McKay |Wanling Xie |Xiaoyu Yang |Andres Acosta |Dana E. Rathkopf |Vincent P. Laudone | +9 more

CONFLICT OF INTEREST STATEMENT Rana R.
Advancing Patient-Centered Outcomes and Equity in Clinical Trials for BCG-Unresponsive Nonmuscle Invasive Bladder Cancer

Sep 7, 2023 | jamanetwork.com | Thomas Hwang |Benjamin Davies |Mark Preston

Advancing Patient-Centered Outcomes and Equity in Clinical Trials for BCG-Unresponsive Nonmuscle Invasive Bladder Cancer From 20% to 40% of patients with nonmuscle invasive bladder cancer (NMIBC) experience disease recurrence after bacillus Calmette-Guérin (BCG) treatment.1 Until recently, there was only a single, relatively ineffective, treatment option approved for patients who are ineligible for or decline cystectomy (valrubicin approved in 1998).
Mark A Preston returns with revolutionary 'training by doing' method

Aug 14, 2023 | lancashirebusinessview.co.uk | Mark Preston

In a proud homecoming, Lancashire's very own Mark A Preston, renowned business growth (SEO) trainer, advisor and speaker, brings his global experience back to his roots. Mark introduces his pioneering 'training by doing' method to Lancashire companies and agencies, offering an exclusive programme that delivers 100 per cent tailored, hands-on, on-site training focused on boosting revenue growth through real-world application.
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)

Jul 5, 2023 | europeanurology.com | Matthias Eiber |Tobias Maurer |Mark Preston |Brian Helfand

AbstractRadiohybrid (rh) 18F-rhPSMA-7.3 is a novel high-affinity prostate-specific membrane antigen (PSMA)-targeting radiopharmaceutical for prostate cancer (PCa) imaging. To evaluate the diagnostic performance and safety of 18F-rhPSMA-7.3 in newly diagnosed PCa patients planned for prostatectomy. Data on 18F-rhPSMA-7.3 were reported from the phase 3 prospective, multicentre LIGHTHOUSE study (NCT04186819).